XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2023
Sep. 30, 2022
Current Assets:    
Cash and cash equivalents $ 29,065,522 $ 41,711,690
Prepaid expenses 5,835,602 2,852,580
Total Current Assets 34,901,124 44,564,270
Property and equipment, net 2,639 4,100
Operating lease right-of-use asset, net 552,205 646,074
Other Assets:    
Deposits 38,062 38,062
In-process research and development 59,400,000 59,400,000
Goodwill 9,346,796 9,346,796
Total Other Assets 68,784,858 68,784,858
Total Assets 104,240,826 113,999,302
Current Liabilities:    
Accounts payable 2,725,593 1,165,378
Accrued expenses 2,250,836 1,405,394
Accrued compensation 1,025,777 1,762,251
Operating lease liability 207,471 196,989
Total Current Liabilities 6,209,677 4,530,012
Deferred tax liability 5,849,800 5,561,800
Operating lease liability – noncurrent 374,831 481,245
Total Liabilities 12,434,308 10,573,057
Commitments and Contingencies
Stockholders’ Equity:    
Preferred stock – $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock – $0.001 par value; 400,000,000 shares authorized; 146,357,797 and 146,211,130 shares issued and outstanding at March 31, 2023 and September 30, 2022, respectively 146,358 146,211
Additional paid-in capital 234,867,917 232,368,121
Accumulated deficit (143,808,137) (129,688,467)
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity 91,206,138 102,825,865
Non-controlling interest 600,380 600,380
Total Equity 91,806,518 103,426,245
Total Liabilities and Equity $ 104,240,826 $ 113,999,302